Key result
Finerenone improves 28-day post-MI survival by ~29 percentage points in murine non-diabetic CKD.
Its licence doesn't allow us to show a copy here.
Why the study?
Does finerenone improve survival and reduce myocardial fibrosis in a murine non-diabetic CKD-MI model?
Does finerenone improve survival and reduce myocardial fibrosis in a murine non-diabetic CKD-MI model?
Absolute Event Rate: 88.9% vs 60%
Finerenone demonstrated cardioprotective and antifibrotic effects in a preclinical model of non-diabetic CKD-MI, potentially involving the EGFR-PI3K-Akt signaling axis.
BACKGROUND Myocardial infarction (MI) complicated by chronic kidney disease (CKD) is associated with adverse outcomes and exacerbated myocardial fibrotic remodeling. Finerenone is a non-steroidal mineralocorticoid receptor antagonist, but its effects and myocardial signaling changes in non-diabetic CKD-MI remain insufficiently characterized. METHODS Network pharmacology identified candidate genes associated with finerenone and CKD-MI, and protein-protein interaction network topology prioritized candidate hub nodes. Molecular docking predicted finerenone-protein binding poses, while 100-ns molecular dynamics simulations characterized the conformational behavior of the modeled complexes under the applied simulation conditions. In a murine non-diabetic CKD-MI model, we assessed survival, left ventricular function, myocardial fibrotic remodeling, and myocardial EGFR, PI3K p85, and Akt phosphorylation. RESULTS Among 188 overlapping candidate genes, eight candidate hub nodes were prioritized. The PI3K-Akt pathway was significantly enriched, with EGFR, PIK3CA, and PIK3R1 among the prioritized nodes. Predicted docking scores ranged from -8.6 to -7.3 kcal/mol, and modeled complexes exhibited stable conformational behavior under the applied simulation conditions. In vivo, finerenone improved 28-day survival (88.9% vs. 60.0% in vehicle-treated CKD-MI mice), preserved left ventricular systolic function, reduced myocardial collagen deposition and fibrotic marker protein levels, and lowered the phosphorylation-to-total protein ratios of EGFR, PI3K p85, and Akt. CONCLUSION Finerenone exhibited cardioprotective and antifibrotic effects in a murine non-diabetic CKD-MI model. Integrated in silico and in vivo data suggest that the EGFR-PI3K-Akt axis is a candidate signaling pathway associated with these protective effects, although its causal contribution remains to be established.
No takes yet. Share an insight, caveat, or question.
Xiang et al. (2026) studied Myocardial infarction complicated by chronic kidney disease (CKD). Finerenone vs. Vehicle was evaluated on 28-day survival. In a murine non-diabetic CKD-MI model, finerenone improved 28-day survival (88.9% vs. 60.0%) and preserved left ventricular systolic function while reducing myocardial fibrosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: